IMRX vs RVMD
IMRX: Immuneering is a clinical-stage oncology company developing a new class of Deep Cyclic Inhibitors designed to overcome the limitations of chronic targeted therapies in cancer treatment. RVMD: Revolution Medicines is a precision oncology company developing targeted therapies to treat RAS-addicted cancers through its proprietary research platform.
Side-by-side fundamentals
| Metric | IMRX | RVMD | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $3.74 | $188.12 | |
| Market cap as of 2026-07-31 (share count; price 2026-10-08) | $242M | $40.3B | |
| ROE FY2025, SEC XBRL | -25.6% | -69.3% | IMRX higher |
| ROA FY2025, SEC XBRL | -24.2% | -48.0% | IMRX higher |
| Debt / equity as of 2026-09-02 | 0.00 | 0.40 | IMRX lower |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 0.91 | 1.05 | |
| 1-year return as of 2026-10-08 close | -42.5% | +293.4% | RVMD higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.